You are here:Home-Research Areas-Cancer-Ovarian Cancer

Request The Product List ofOvarian Cancer Ovarian Cancer

Cat. No. Product Name CAS No. Information
PC-60483

Pamiparib

1446261-44-4

Pamiparib (BGB-290, BGB290) is a highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.

Ovarian Cancer

Phase 2 Clinical

PC-60186

Cridanimod

38609-97-1

Cridanimod (10-carboxymethyl-9-acridanone, 10-CMA, XBIO-101) is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route; displays extraordinary activity in phosphorylating IRF3 in the murine system; also increases progesterone receptor (PrR) expression in endometrial tissue.

Ovarian Cancer

Phase 2 Clinical

PC-42266

Triapine

143621-35-6

Triapine (3-AP, PAN-811, OCX191, NSC 663249) is a potent ribonucleotide reductase inhibitor with broad spectrum antitumor activity.

Ovarian Cancer

Phase 2 Clinical

PC-45909

Trabectedin

114899-77-3

Trabectedin (Ecteinascidin-743, ET-743, Ecteinascidin) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata that shows remarkably anticancer activity in a variety of in vitro and in vivo systems; a DNA minor groove, guanine-specific alkylating agent; shows hign potency against ovarian carcinoma xenografts.

Ovarian Cancer

Approved

PC-42681

MK-4827

1038915-60-4

MK-4827 (Niraparib, MK4827) is a highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2; inhibits PARP activity with EC50=4 nM in a whole cell assay, and inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10−100 nM range; well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.

Ovarian Cancer

Approved

PC-35571

ORIC-101

2222344-98-9 ORIC-101 (ORIC101) is a highly potent, selective steroidal glucocorticoid receptor (GR) antagonist (IC50=5.6 nM) with reduced androgen receptor (AR) agonistic activity; dose-dependently reduces the expression levels of two established GR target genes, GILZ and FKBP5 with IC50 of 24.9 and 19.5 nM in human PBMCs; demonstrates in vivo antitumor activity by enhancing response to chemotherapy in the GR+ OVCAR5 ovarian cancer xenograft model.

Ovarian Cancer

Phase 1 Clinical

PC-43422

LY2940680

1258861-20-9 LY2940680 (Taladegib) is potent Smoothened (SMO) receptor antagonist, potently inhibits Hedgehog (Hh) signaling with IC50 of 6.3 nM in Gli-luc reporter assyas; inhibits medulloblastoma cell proliferation isolated from Ptch+/–p53–/– mice with IC50 of 43.5 nM; demonstrates anti-tumor activity in vivo with advanced basal cell carcinoma (BCC) and other malignancies.

Ovarian Cancer

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com